Therapy Candidate IMU-838 Shows Strong Activity in Preclinical Models of UC, Immunic Announces
News
IMU-838, Immunic Therapeutics‘ lead therapy candidate for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), shows strong activity in cellular and animal models of disease, preclinical studies ... Read more